Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Standard BioTools ( (LAB) ) has provided an announcement.
Standard BioTools reported first quarter 2026 revenue of $21.1 million, up 5% year over year, driven by 35% growth in consumables to $11.0 million, while instruments revenue declined 33% to $4.5 million amid capital-constrained end markets. The company improved operating efficiency through restructuring, cutting operating expenses by 37% to $23.8 million and shrinking its adjusted EBITDA loss by 78% to $3.1 million, and with roughly $550 million in cash and investments following the completed sale of SomaLogic to Illumina, it maintained full-year 2026 revenue guidance of $80 million to $85 million and highlighted flexibility to pursue inorganic growth and strengthen its path to profitability.
Net loss from continuing operations narrowed to $14.6 million in the first quarter of 2026 from $23.4 million a year earlier, aided by lower expenses and stable gross margins around the mid-50% range on both GAAP and non-GAAP bases. Management emphasized that the stronger balance sheet, including a $25 million earnout received after quarter end, positions the company to redeploy capital into acquisitions and other strategic initiatives, potentially accelerating its transformation despite ongoing pressures in capital equipment demand and broader macro and funding constraints affecting its end markets.
The most recent analyst rating on (LAB) stock is a Hold with a $1.35 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
The score is held down primarily by weak financial performance (sharp revenue contraction, large ongoing losses, and persistent cash burn) and bearish technicals (below key moving averages with negative MACD). Corporate events are mixed—improved liquidity from the divestiture helps, but Nasdaq compliance risk is a meaningful negative—while valuation offers limited support due to continued losses and no dividend.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc., listed on Nasdaq under the ticker LAB, operates in the life sciences tools industry, providing instruments, consumables and field services used in applications such as microfluidics. The company targets research and clinical end markets, with a focus on consumables-driven recurring revenue and strategic capital deployment supported by a substantial cash and investment balance.
Average Trading Volume: 2,534,033
Technical Sentiment Signal: Sell
Current Market Cap: $365M
For detailed information about LAB stock, go to TipRanks’ Stock Analysis page.